节点文献

格列齐特缓释片处方及工艺研究

Formula and Preparation Technology of Gliclazide Controlled-release Tablets

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 张威刘智查伟赵银鹰张执一刘星宇

【Author】 ZHANG Wei, LIU Zhi, ZHA Wei, ZHAO Yinying, ZHANG Zhiyi, LIU Xingyu(Jiangxi Pharmaceutical Co. Ltd., Nanchang 330052, China)

【机构】 江西制药有限责任公司江西制药有限责任公司 南昌市330052南昌市330052

【摘要】 目的:筛选和研究格列齐特缓释片处方及工艺。方法:制备不同处方的格列齐特缓释片并进行释放度测定,筛选最佳处方及制备工艺。结果:确定了以羟丙基甲基纤维素(HPMC)K4M、E50处方量分别为17、35g作为基本骨架材料,磷酸氢钙91g为填充剂,硬脂酸镁为润滑剂的处方;由其制备的格列齐特缓释片释放度结果与参比样品基本相似。结论:以最佳处方制备的格列齐特缓释片释放度符合《中国药典》标准。

【Abstract】 OBJECTIVE: To optimize the formula and preparation technology of gliclazide controlled-release tablets. METHODS: Gliclazide controlled-release tablets were prepared in different formulations and the release rates of the prepared tablets were determined to obtain the optimum formula and preparation technology. RESULTS: The optimized formula of gliclazide controlled-release tablets were determined as follow: with HPMC(K4M)=17g and HPMC(E50)=35g as matrix materials; Calcium hydrogen phosphate=91g as the bulking agent and magnesium stearate as lubricant. Gliclazide controlled-release tablets showed a similar release rate as the reference samples. CONCLUSION: The releasing rate of gliclazide controlled-release tablets prepared in the optimized formula is in line with the standards stated in China Pharmacopeia.

  • 【分类号】TQ463;R94
  • 【被引频次】2
  • 【下载频次】420
节点文献中: 

本文链接的文献网络图示:

本文的引文网络